Corient Private Wealth’s Gossamer Bio GOSS Stock Holding History

Corient Private Wealth’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$927K	Buy	5,632,698 +1,647,315	+41%	+$460K	﹤0.01%	1867
2026 Q1	$1.31M	Buy	3,985,383 +139,498	+4%	+$219K	﹤0.01%	1488
2025 Q4	$11.9M	Buy	3,845,885 +3,825,879	+19,124%	+$10.9M	0.02%	519
2025 Q3	$52.6K	Sell	20,006 -3,673,677	-99%	-$8.1M	﹤0.01%	2496
2025 Q2	$4.54M	Buy	3,693,683 +302,200	+9%	+$330K	0.01%	724
2025 Q1	$3.73M	Hold	3,391,483	–	–	0.01%	764
2024 Q4	$3.07M	Hold	3,391,483	–	–	0.01%	847
2024 Q3	$3.35M	Hold	3,391,483	–	–	0.01%	886
2024 Q2	$3.06M	Buy	3,391,483 +119,213	+4%	+$89.2K	0.01%	861
2024 Q1	$3.86M	Buy	3,272,270 +334,339	+11%	+$368K	0.01%	782
2023 Q4	$2.68M	Buy	2,937,931 +965,092	+49%	+$713K	﹤0.01%	882
2023 Q3	$1.64M	Buy	1,972,839 +602,653	+44%	+$694K	﹤0.01%	987
2023 Q2	$1.64M	Buy	1,370,186 +9,800	+0.7%	+$12.2K	﹤0.01%	963
2023 Q1	$1.71M	Buy	1,360,386 +1,191,666	+706%	+$2.28M	﹤0.01%	897
2022 Q4	$366K	Buy	+168,720	New	+$1.39M	﹤0.01%	1258

Other funds holding GOSS

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DIG

DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Corient Private Wealth's GOSS Position: Q2 2026 in Review

Corient Private Wealth increased its Gossamer Bio (GOSS) stake by 41% in Q2 2026, buying an estimated $460K and bringing the position to 5,632,698 shares worth $927K. The position accounts for ﹤0.01% of the portfolio, ranked #1867.

Corient Private Wealth first reported a position in GOSS in Q4 2022 and has held it in 15 quarters since. The position peaked at $11.9M in Q4 2025. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

Corient Private Wealth held 5,632,698 shares of Gossamer Bio worth $927K as of Q2 2026.
Corient Private Wealth bought 1,647,315 Gossamer Bio shares in Q2 2026, an estimated $460K.
Gossamer Bio made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1867 holding.
Corient Private Wealth first reported a position in Gossamer Bio in Q4 2022 and has held it in 15 quarters since.
Corient Private Wealth's Gossamer Bio position peaked at $11.9M in Q4 2025.
170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.